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Purpose: Testing the safety and foreign body reaction (FBR) of a nitinol self-expandable
carbon-coated stent system in the porcine animal model at different follow-up (FU) periods.
Methods: Fifteen minipigs received 30 carbon-coated self-expandable nitinol stents in iliac
arteries. Explants were carried out at 7 (3 animals), 30 (4 animals), 90 (4 animals) and 180 (4
animals) day FU, for evaluation of acute, sub-acute and chronic biological response to the
implanted devices. Histological, immunohistochemical, histomorphometric and scanning
electron microscopy (SEM) analyses were performed to assess inflammatory reaction,
endothelialization process, neointimal growth and cellular composition. Results: Thirty
stents were successfully implanted. No mural thrombi were observed at gross examination
or by angiography. Histologically no significant inflammatory reaction was detected: the
stents appeared covered by a thin monolayer of endothelial cells even at 7 day FU. The
neointima presented homogeneous growth and moderate thickness after 30, 90 and 180
days explants (0.38 ± 0.36 mm, 0.33 ± 0.30 mm, 0.27 ± 0.25 mm respectively). Internal and
external elastic laminae were intact in 95% of stented arteries. Histological data validations
of vessel endothelialization was obtained with SEM for the seven day follow-up group.
Conclusions: This study showed good remarkable technical performances, minimal FBR
and biocompatibility comparable with other available pre-clinical experimentations.
C© 2005 Springer Science + Business Media, Inc.
1. Introduction
Arterial occlusive pathologies represents the third
major cause of death in developed countries. To treat
these vessel stenosis, in the 80’s new mini-invasive pro-
cedures were introduced. This complex of techniques,
defined as interventional cardiology (IC), have dramat-
ically modified revascularisation strategies [1]. In IC
procedures arterial occlusions are treated without any
surgical operation with consequent lower risk for pa-
tients and no need for long confinement in bed. At the
beginning, these procedures were mainly represented
by percutaneous transluminal angioplasty (PTA). In this
technique a catheter containing an inflatable balloon at
the distal part is advanced along the vessel and when
target site is reached the lumen of the artery is widened
by mean of balloon inflation. This has been proven to be
effective in the acute situation; unfortunately the me-
chanical stress itself, caused by the balloon dilation,
became a further cause of re-stenosis. In the last few
years PTA has been almost completely substituted by
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stenting. In this case, the distal part of the catheter con-
tains a stent, i.e. a slotted tube, that is left in place
upon the inflation of the balloon. Several clinical and
pre-clinical studies [2, 3] have demonstrated a remark-
able increase in procedural success and reduced post-
procedural complications of stenting vs. PTA. Despite
these relevant clinical results, in-stent restenosis (ISR)
is still high, ranging from 10% to 50% of all coronary
stents implantations [4–7].
In-animal experimentations demonstrated that this
ISR is due both to stent composition and device
surface treatment. Deployment technique itself can
also disrupt the endothelial cell monolayer causing
platelets activation, secretion of inflammation medi-
ators, macrophages recruitment, smooth muscle cells
(SMC) activation and proliferation and extracellular
matrix (ECM) deposition conducing to neointimal
proliferation [8, 9].
Balloon expandable (BE) stents first developed for
coronary arteries were then applied to the peripheral
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district [10, 11]. But since the pioneer work of Dotter
et al. [12] on nickel titanium alloy (nitinol) as a source
for endovascular devices, it seemed clear that these
metal alloys could be exploited for peripheral stent
design.
As a matter of fact, Nitinol, due to its super elasticity
offers a better resistance to radial forces than BE stents.
Nitinol has also shape memory allowing for a specific
implantation technique: the stent is kept in a collapsed
condition inside a delivery catheter. After the implant
site is reached, a catheter sleeve is removed so that
the stent can automatically expand, reaching the vessel
wall.
The aim of this in-animal study is the assess-
ment of procedural performances and biological fea-
tures in terms of restenosis evaluation of a new self-
expandable carbon coated stent (Flype Carbostent,
Sorin Biomedica—Italy) in the porcine animal model.
2. Materials and methods
The implant procedures were performed at the Insti-
tute Mutualiste Montsouris (IMM) in Paris, in accor-
dance with the guidelines of the National Institute of
Health for the Care and Use of Laboratory Animals
[13]. The histological and histomorphometric analyses
were conducted at the Biomaterials Laboratory of Vet-
erinary Medicine School at University of Turin, Italy.
2.1. Stent description
Flype Carbostent peripheral stents (Fig. 1) are self
expandable tubular laser cut, nitinol devices with
multi-segmented design with a fifteen circumferential
V-shaped struts geometry providing stent expansion
during deployment and radial resistance after implant;
V-tracts are interconnected by longitudinal links in or-
Figure 1 The Flype stent. Detail of the unconstrained stent showing strut design and tantalum radio-opaque markers.
Figure 2 The stent delivery system: 1) Proximal body of the external sheath 2) Control knob 3) Built-in mechanism 4) Luer connector 5) Release
system handle.
der to improve the flexibility along the stent major axis
and aid an homogeneous deployment. Struts thickness
is 200 µm and struts width is 100 µm. The intercon-
nected cellular design allows minimal foreshortening
and provides an optimal lesion coverage, approximately
21% and outward radial force to the luminal vessel
surface.
Flype stent was designed exploiting nitinol pseudo-
elasticity effect. In particular, stent geometry and
Austenite finish temperature have been choosen in order
to minimize the stent continuing opening force acting
on the vessel wall (COF) and to maintain the vessel pa-
tency thanks to an optimal value of stent resistive force
(RRF).
The over-the-wire release system (Fig. 2) consists of
an external retractable sheath (5.7 Fr proximally, 6 Fr
distally), that contains in the distal end the stent coiled
along the longitudinal axis. The proximal part of the de-
livery system contains an internal core for the insertion
of the guide wire and a delivery system handle.
To treat the lesion the catheter is advanced to the
target site. Upon retraction of the sheath the stent ex-
pands due to its superelastic properties and reach the
vessel wall.
The stent is prepared with a nickel titanium alloy
according to the ASTM F2063 standard. it’s than laser
cut, deburred, heat set and electropolished. Heat pas-
sivation is achieved at about 500 ◦C and the stent is
shaped and fixed at its nominal diameter. The heat treat-
ment confers the correct mechanical characteristics and
induces the desired TiO2 layer at device surface; elec-
tropolishing confers the final surface finishing, the so
called mirror polishing. The stent is then CarbofilmTM
coated. This turbostratic carbon film has a thickness
of 0.3–0.5 µm and has the same structure of the py-
rolitic carbon but is deposited at room temperature in
high vacuum [14, 15]. Metal implantable devices when
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coated with Carbofilm become similar to pyrolytic car-
bon in terms of tissue and blood compatibility. Three
tantalum radio-opaque markers are located at each stent
ends.
2.2. Animal model
The experimental study was performed on 15 non-
atherosclerotic minipigs weighing between 35 and
45 Kg. The pigs were sacrificed at 7 (n = 3), 30 (n = 4),
90 (n = 4) and at 180 days (n = 4). All selected ani-
mals were visited three days before implants, to verify
the clinical conditions. Two days before interventions
they were submitted to a pharmacological treatment
based on acetylsalicylic acid (ASA) (300 mg/day) and
nifedipine (30 mg/day). A 24-hour food and liquids
fasting before intervention was adopted.
2.3. Stent deployment
Animals were anesthetized by an intramuscular
injection of ketamine (10 mg/kg) and azaperone
(0.5 mg/kg). Deep anesthesia was induced by intra-
venous injection of thiopental (10 mg/kg) and main-
tained under a gaseous mixture of isoflurane (Abbott
Laboratories, Illinois—USA) (2%) in pure oxygen.
Iliac arteries were reached via surgically isolated
right carotid artery. The procedural anticoagulation was
obtained by a bolus of of heparin (100 I.U./kg) injected
intravenously.
An 8F introducer (Medex Medical, Rossendale
Lancashire—UK) was positioned and a 8F guid-
ing catheter Judkins right 3.5–4 (Medi-Dyne,
Queensbury—NY) was introduced through this chan-
nel. An angiogram of the target vessels, by means of
fluoroscopy, was obtained, using the guiding catheter
as dimensional reference, in order to determine the
diameter of the vessel lumen. For each frozen frame
were injected 5 cc of contrast medium. A guide-wire
0.035” “support” (Kimal, Uxbridge—UK) was used to
progress the stent delivery system to the target vessel.
The stent is then automatically deployed by means of
the release system handle. Stents were placed in iliac
arteries without any injury prior to stent placement.
Post-procedural angiogram was performed to assess
the complete and correct expansion to the final nominal
diameter.
All stents were implanted by the same operator.
6.0 mm diameter and 40 mm nominal length stents
were tested. No post-deployment balloon dilation was
applied.
Pigs were then submitted to anti-platelet treatment
with ASA 300 mg/day until the explant day. All an-
imals survived until the planned explant day. At the
end of the scheduled follow-up, each animal under-
went a further angiographic control in order to as-
sess the vessel patency. Before euthanasia, 14.000 I.U.
of heparin were intravenously administrated. Animals
were euthanized by an intravenous injection of bar-
biturate (60 mg/kg), following the guidelines of the
“2000 Report of the AVMA Panel on Euthanasia”
[16].
2.4. Microscopic analysis, morphological
evaluation and morphometrical
analysis
After the explant, iliac arteries were excised, washed by
mean of 500 ml of heparined physiological solution and
then placed in 10% buffered formalin for 48 h and then
washed overnight in water. Arteries underwent X-ray
assessment, in order to evaluate the absence of distor-
tion and structural failure of the stent struts. The stented
portion of each artery was dehydrated in ascending
concentrations of ethanol, subsequently infiltrated and
embedded in methylmethacrylate plastic. The sealed
vials containing stented samples were placed in −20 ◦C
freezer for polymerisation.
Cross-sections, 1.5 mm thick, were cut from the
proximal, middle and distal portion of the embed-
ded stented specimens, using a rotating precision saw
(Tronconneuse Presi P100, Grenoble, France). Struts
were manually removed from these cross-sections in
order to allow the preparation for microtome cutting.
The sections were then glued on a specimen holder;
5 µm slices were cut with a tungsten carbide blade
microtome (Microtome 2135, Leica, Heerbrugg) and
stained using Mayer’s emallume/eosine-floxine and
Movat pentachrome stain. The vessel segments proxi-
mal and distal to the stents were embedded in paraffin,
sectioned and stained as described above.
Neointimal thickness was measured as the distance
from internal elastic lamina (IEL) to the luminal border
both at and between each stent strut.
The injury score [17] was calculated for each stent
strut; the presence of granulomas, vacuoles and neo-
angiogenesis were also identified for each stent strut.
The neointimal inflammation score [18], the presence
and rate of inflammatory cells in the neointimal layer,
was evaluated in five randomly chosen 40× micro-
scopic fields adjacent to the stent struts and neointimal
inflammatory response was graded as: 0 (no inflamma-
tion), 1 (0–500 inflammatory cells/mm2), 2 (500–800
inflammatory cells/mm2) and 3 (over 800 inflammatory
cells/mm2).
Immunohistochemistry (IHC) was performed on
paraffin sections obtained after struts removal for all
collected samples. Macrophages (CD68, Dako, Carpin-
teria, CA, USA) and von Willebrand factor (Dako)
were targeted in 7-days FU group. Alpha-actin (Dako)
for smooth muscle cells (SMC) identification was per-
formed for each group of FU for a qualitative evaluation
of neointima and media composition.
Scanning electron microscopy (SEM) was performed
on 7-day FU group. Specimens were dehydrated, lon-
gitudinally cut, critical point dried (BAL-TEC AG,
Fo¨hrenweg, Liechtenstein), and finally gold coated
(BAL-TEC AG). Specimens were observed with a
Cambridge S200 (LEO, Cambridge, UK) at operating
voltage varying from 15 to 20 kV and 1536 × 1200
pixels; digital images were acquired via Pixie-3000,
a real time active SEM framestore (Deben software,
Stowupland, UK).
Histomorphometric analysis was performed using an
image analysis software (Image Pro Plus; Media Cy-
bernetics, Silver Spring, MD) on stented segments and
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on correspondent proximal and distal portion of iliac
arteries. For each stented section the following param-
eters were calculated: lumen area, area within internal
elastic lamina (IEL) and area within external elastic
lamina (EEL). Medial area was obtained subtracting
the EEL area from IEL area, while neointimal area was
acquired as a subtraction of the lumen area from the
IEL area. The percentage of stenosis was calculated
following the formula [10]:
% AREA STENOSIS = [IEL − L]
IEL
× 100
All continuous histomorphometric variables were ex-
pressed as mean ± standard deviation.
3. Results
3.1. Macroscopic and angiographic findings
30 stents were successfully implanted in orthotopic
position. The angiographic controls (Fig. 3(a)) per-
formed after stent deployment showed stents expanded
to the nominal final diameter, pre-explant angiogram
(Fig. 3(b)) showed no acute or subacute stent thrombo-
sis at short and mid term follow-ups (7 and 30 days). A
moderated neointimal proliferation was observed in 90
and 180 day FU groups. At X-ray assessment no stent
distortions or structural fractures were found.
3.2. Light microscopy and morphometry
Microscopic evaluation was performed on all stented
vessels, subdivided in 4 different periods of follow-up.
A total of twenty seven arteries specimens were submit-
ted to histological examination (3 arteries from 7-day
FU group, 8 arteries from the 30-day FU group, 8 arter-
ies from the 90-day FU group and 8 arteries from the
180-day FU group). For a complete set of morphomet-
rical data regarding Flype stents see Table I.
3.2.1. 7-day follow-up
At 7 day FU 3 animals were sacrificed and three stents
were submitted to SEM analysis and three to histo-
logical evaluation. Vessels were fully endothelialized
(Figs. 4(a), 5(a), and 6), moderate symmetrical neoin-
timal proliferation (neointimal thickness of 0.04 ±
Figure 3 a) Post procedural angiogram of implanted iliac artery - b) Long term follow up pre-explant angiorgram (180 day FU) showing the vessel
patency.
TABLE I Flype stents—morphometric analysis
7 days FU 30 days FU 90 days FU 180 days FU
IEL (mm2) 19.26 ± 1.77 17.70 ± 2.03 18.19 ± 2.55 16.64 ± 1.40
EEL (mm2) 22.60 ± 1.76 20.53 ± 2.32 21.13 ± 3.12 19.13 ± 1.65
Lumen area 17.79 ± 1.81 13.10 ± 3.35 13.23 ± 3.26 12.50 ± 2.92
(mm2)
% stenosis 7.67 ± 1.70 26.41 ± 15.12 27.16 ± 14.50 25.08 ± 15.09
Neointimal 0.04 ± 0.02 0.27 ± 0.21 0.33 ± 0.30 0.27 ± 0.25
thickness
(mm)
Neointimal 1.47 ± 0.29 4.60 ± 2.70 4.86 ± 2.81 4.14 ± 2.56
area (mm2)
Injury Score 0 0.09 ± 0.22 0.10 ± 0.18 0.31 ± 0.48
Legend: IEL = Internal Elastic Lamina; EEL = External Elastic Lamina.
0.02 mm, neointimal area of 1.47 ± 0.29 mm2), no
particular inflammatory response (inflammation score
0.00 ± 0.00) was detected, small blood clots and vac-
uoles were detected only around stent struts. Internal
elastic lamina (IEL) and external elastic lamina (EEL)
were always intact (injury score 0.00 ± 0.00).
3.2.2. 30 day follow-up
At 30 day FU 4 animals were sacrificed; (Figs. 4(b)
and 5(b)), histological findings showed complete ves-
sel endothelialization. A symmetrical neointimal pro-
liferation was observed in four specimens; the neoin-
timal growth was asymmetrical in the remaining ones.
Just in 1 stent a remarkable neointimal proliferation
was detected (neointimal thickness 1.15 ± 0.21 mm
and neointimal area 14.12 ± 2.68 mm2, injury score
0.03 ± 0.03) together with vacuoles and blood clots
around the stent struts, whereas the remaining stents
showed mean neointimal thickness of 0.27 ± 0.21 mm,
neointimal area 4.60 ± 2.70 mm2 and injury score
0.09±0.22. Neointima was mainly composed by SMC
embedded in proteoglican matrix. No inflammatory re-
action was detected (inflammation score 0.00 ± 0.00).
IEL and EEL were always intact and media appeared
regular in all the examined specimens.
3.2.3. 90 day follow-up
At 90 day FU 4 animals were sacrificed; all stents
were subjected to histological study (Figs. 4(c)
and 5(c)). The arteries showed mean neointimal
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Figure 4 Flype stent—full vessel images (magnification circa 20×), Histological sections at a) 7 days FU b) 30 days FU c) 90 days FU and d) 180
days FU, Movat pentachrome stain, bar lenght = 1 mm.
Figure 5 Flype stent—Detail of stent struts, 150× a) 7 days FU b) 30 days FU c) 90 days FU and d) 180 days FU, Movat pentachrome stain, bar
lenght = 150 micron. Asterisk indicates the stent struts.
thickness of 0.33 ± 0.30 mm and neointimal area of
4.86 ± 2.81 mm2. Generally all stents showed symmet-
rical neointimal proliferation but in the case of two
stents, belonging to the same animal, a remarkable
asymmetrical neointimal growth was observed. Neoin-
tima was mainly composed of SMC embedded in a
proteoglican matrix. In three specimens the IEL was
disrupted by the stent struts (injury score 0.10 ± 0.18).
There was no evidence of inflammatory process (in-
flammation score 0.00 ± 0.00).
3.2.4. 180 day follow-up
At 180 day FU 4 animals were sacrificed; all eight arter-
ies collected (Figs. 4(d) and 5(d)), four arteries showed
symmetrical neointimal growth while four arteries had
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Figure 6 SEM of 7 days FU Flype stents a) Confluent and regular carpet of neo-endothelial cells, 31× b) Detail of the previous image showing
neo-endothelial cells with the typical rhomboid shape covering stent strut, 340×.
a slightly asymmetrical proliferation (neointimal thick-
ness of 0.27 ± 0.25 mm and neointimal area of 4.14 ±
2.56 mm2). IEL and EEL were always intact except in
one stent, where the IEL was stressed by stent struts
(injury score 0.31 ± 0.48). No chronic inflammatory
reaction was detect at stent struts level (inflammation
score 0.28 ± 0.461).
3.3. Immunohistochemistry
Immunohistochemistry for Von Willebrand factor on
7 days FU group revealed full endothelialization of
stented arteries with a positivity of neo-endothelial
cells. Rare CD68 positive cells were found in 7 days
FU and this positivity was absent at 30 and 180 day FU
confirming a moderate inflammatory response in the
short term. Neointima showed an intense staining for
alpha actin particularly in 28 days FU group.
3.4. Scanning electron microscopy
The examination of three 7 day FU group iliac stents
(Fig. 6) confirmed the presence on the struts of a con-
fluent and regular carpet of neo-endothelial cells with
the typical rhomboid shape; only a negligible amount
of platelets and inflammatory cells were detectable.
4. Discussion
The introduction of the nitinol as a source for
endovascular devices has provoked some concerns in
the medical community due to the its high nickel con-
tent; the toxic effect of nickel is in fact well known
and it’s mainly related to the production of reactive
oxygen species due to oxidation and redox cycling be-
tween Ni3+ and Ni2+ ions [19]. Recent studies [20] have
demonstrated that heat passivation and electropolishing
techniques of nitinol stents result in formation of an en-
riched TiO2 layer on the device surface which inhibits
the redox cycling of Ni and consequently reduces the
amount of oxidative stress directed against endothelial
cells. Further pre-clinical investigations [21–23] have
proven that nitinol has a biocompatibility comparable
or even superior to stainless steel stents.
In the case of the present study the examined stents
were heat passivated, electropolished and Carbofilm
coated; the last layer being the real interface with the
biological tissues. Carbofilm coated devices become
similar to pyrolytic carbon in terms of tissue and blood
compatibility [24]; Evidence of safety and effectiveness
of this coating comes from long-term clinical experi-
ence in heart valve implants and stents implants [15].
In our study all stents were tested in a normocholes-
terolemic pig model with no previous injury or over-
sizing of the implanted devices. The pig model was
adopted as in comparison with other animal models,
e.g. the dog, it responds to a vessel wall injury by de-
veloping a thick neointima virtually identical to the hy-
perplasia found in humans in terms of cell size, cell
density and histopathological appearance. Major model
limitations consist of the use of disease-free arteries
instead of atherosclerotic ones. A full atherosclerotic-
restenosis animal model is not yet available. Although
neointima formation through SMC proliferation, mi-
gration and ECM secretion is identical to humans and
at the moment the pig model is the gold standard for
stent pre-clinical evaluation.
All collected vessels were patent at explant, no mu-
ral thrombi were observed. All implanted stents were
correctly deployed in the vessel without any malappo-
sition and endothelialization, that has been proven to
be crucial in limiting neointimal formation, was com-
plete at 7-day FU with rhomboid-like neo-endothelial
cells covering stent struts as shown from SEM and IHC
results.
The tested stents presented (graph 1) a typical curve
for measured morphometrical parameters with a neoin-
timal thickness, area and % stenosis higher at 30 day
FU, in response to the inflammation which normally
has a peak circa at 7 day [25, 26] and decreasing values
for longer FU suggesting a mechanism of vessel remod-
elling mainly due to the ECM as the SMC population of
the neointima remains practically stable at different FU
(4341±788 cells/mm2 at 30 day FU, 4792±1201 cells
at 90 and 4758 ± 1278 cells/mm2 at 180 day FU) with
no statistically significant difference.
The moderate 180 day FU neointimal thickness and
cellularity results are particularly interesting as this FU
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is considered to be akin to two or three years response
in humans [27]. This was clearly detectable also in the
images at high magnification (Fig. 5(b)). IEL area val-
ues were not significantly different between 30 day FU
and 180 day FU suggesting a good behaviour in terms
expansion properties even at longer FU with no late
expansion. In a recent study by Taylor et al. [28] niti-
nol devices in fact showed a tendency to late expansion
and there is some evidence that a prolonged expansion
could act as a continuous inflammatory stimulus re-
sulting in a larger amount of neointima formation thus
cancelling the nitinol advantage for no high pressure
balloon deployment.
IHC results have shown no particular inflammatory
response other than a normal FBR in acute FU with
sparse macrophages around stents struts. Macrophage
positivity decreases in longer FU confirming absence
of chronic inflammation. Staining for alpha actin (a
specific SMC marker) confirmed histological results
of neointima composition. At 28 day FU Movat pen-
tachrome stain revealed a marked ECM which decrease
in longer FU as observed from morphometrical data
analysis.
A comparison with other pre-clinical trials is par-
ticularly difficult, due to the different animal models,
experimental settings, stent types, stent designs, diets,
injury models and procedure manoeuvres adopted.
In that context a direct comparison is impossible; a
wider comparison could be done and present study re-
sults compared, in terms of neointimal thickness and
injury score at 30 and 180 day FU with a similar
pre-clinical trial in the porcine iliac arteries by Ver-
heye et al. [29]. The tested stents resulted in values of
neointimal thickness and injury score respectively of
0.27 ± 0.21 mm and 0.09 ± 0.22 for 30 day FU and
0.27 ± 0.25 mm and 0.31 ± 0.48 for 180 day FU while
for the EndoStent tested by Verheye results were re-
spectively 0.65 ± 0.13 mm and 0.86 ± 0.05 for 30 day
FU and 0.86±0.18 mm and 1.21±0.17 for 180 day FU.
Results for the studied stents were similar or even better
at each FU but it must be pointed out that in Verheye’s
work a injury was provoked just before stent implanta-
tion by balloon overstretch (balloon artery ratio 1:1.2).
Neointimal thickness results can be compared to
the work of Froelich et al. [30] whose results were
respectively 1.105 ± 0.485 mm at 90 days FU and
1.212 ± 0.167 mm at 180 day FU. Also in this case
a direct comparison is incorrect, in fact an atherogenic
diet was adopted for 6 weeks to increase blood choles-
terol values in order to mimic the situation in humans;
on day 14 of that diet an injury was provoked by means
of inflation and pull back for three times of a Fogarty
balloon catheter. A last comparison can be drawn with
Harnek et al. [31], assuming its group 3 for reference,
represented by 30% oversized self expandable stents
implanted without any previous PTA, and the 56 day
FU (an intermediate value between the 30 and 90 day
FU of the present study) results were 2.69 ± 1.97 mm2
for neointimal area and 0.26 ± 0.08 for injury score.
In that case results from Harnek were comparatively
better in terms of neointimal area but not in terms of
injury score.
5. Conclusions
All findings obtained through morphological, IHC,
SEM and morphometrical analysis in this pre-clinical
investigation in the normocholesterolemic porcine
model, i.e.: absence of mural thrombi, low inflam-
matory response at acute and chronic FU, early re-
endothelialization, reduced neointimal proliferation de-
creasing with longer FU suggest that these devices were
safe and presented acceptable level of biocompatibility
comparable with other already published in vivo cited
works, bearing in mind the underlined differences in
terms of oversizing and injury model adopted.
The biocompatibility of that stent together with zero
risk of balloon rupture and no late expansion together
with superelastic properties, suggest a future use in
clinical experimentation and practice.
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